Workflow
AMP platform
icon
Search documents
Elicio Therapeutics Secures $10 Million in Financing
Globenewswireยท 2025-06-04 12:00
Core Viewpoint - Elicio Therapeutics has secured a $10 million senior secured promissory note to extend its operational runway into Q1 2026, supporting its clinical development initiatives, particularly the AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025 [2][4]. Financial Summary - The company received gross proceeds of $10 million from the Note Financing, which bears an interest rate of up to 12.5% and matures on June 3, 2028 [3]. - The financing includes a 24-month interest-only period, with interest accrued during the first 12 months payable in a lump sum starting from the thirteenth month [3]. Product Development - Elicio's lead product candidate, ELI-002, targets mKRAS-driven tumors, which account for approximately 25% of all solid tumors [4][5]. - ELI-002 is currently being studied in a randomized clinical trial for mKRAS-positive pancreatic cancer and has shown promising Phase 1 data, including a 16.3-month median recurrence-free survival and a 28.9-month median overall survival [4][6]. Technology Platform - Elicio's proprietary Amphiphile (AMP) platform is designed to enhance the education and activation of cancer-specific T cells, aiming for durable cancer immunosurveillance [4][7]. - The AMP technology allows for targeted delivery of immunotherapeutics to lymph nodes, potentially leading to superior clinical outcomes compared to conventional therapies [7][8]. Future Plans - The company plans to explore combination regimens for ELI-002 in treating pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer, leveraging robust interest from clinical investigators [4]. - Elicio intends to expand ELI-002 to other indications, including mKRAS-positive lung cancer, and is developing additional off-the-shelf therapeutic cancer vaccine candidates [4][6].
System1(SST) - 2025 Q1 - Earnings Call Transcript
2025-05-06 22:02
System1 (SST) Q1 2025 Earnings Call May 06, 2025 05:00 PM ET Company Participants Kyle Ostgaard - Vice President of FinanceMichael Blend - Co-Founder and CEOTridivesh Kidambi - CFODaniel Kurnos - Managing Director, Internet & Media Equity Research Conference Call Participants Tom Forte - Managing Director & Senior Consumer Internet Analyst Kyle Ostgaard Thank you for standing by, and welcome to the first quarter twenty twenty five earnings conference call for SystemOne. Joining me today to discuss SystemOne ...
System1(SST) - 2025 Q1 - Earnings Call Transcript
2025-05-06 21:00
System1 (SST) Q1 2025 Earnings Call May 06, 2025 05:00 PM ET Speaker0 Thank you for standing by, and welcome to the first quarter twenty twenty five earnings conference call for SystemOne. Joining me today to discuss SystemOne's business and financial results are Co Founder and Chief Executive Officer, Michael Blend and Chief Financial Officer, Trudhavish Kadambi. A recording of this conference call will be available on our Investor Relations website shortly after this call has ended. I'd like to take this ...